Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 72 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Friedreich's Ataxia Clear all

Conditions: Friedreich Ataxia
Interventions: Elamipretide; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 16 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Friedreich's Ataxia
Interventions: GV101, Placebo; Drug
Lead sponsor: Graviton Bioscience Corporation; Industry
Eligibility: 16 Years to 40 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Eatontown, New Jersey

Conditions: Spinocerebellar Ataxia - All Sub-types, Friedreich's Ataxia
Interventions: Ataxia rating scale; Other
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Friedreich Ataxia
Interventions: Omaveloxolone; Drug
Lead sponsor: Biogen; Industry
Eligibility: 16 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 4
States / cities: Los Angeles, California • Aurora, Colorado • Gainesville, Florida + 1 more

Conditions: Friedreich's Ataxia (FA)
Interventions: SGT-212; Drug
Lead sponsor: Solid Biosciences Inc.; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 3
States / cities: Los Angeles, California • Columbus, Ohio • Philadelphia, Pennsylvania

Conditions: Neurologic Disorder, Stroke, Spinal Cord Injuries, Cerebral Palsy, Hemiplegia, Hemiparesis, Multiple Sclerosis, Parkinson Disease, Trauma, Brain, Transverse Myelitis, Friedreich Ataxia
Interventions: Seated exercise; Behavioral
Lead sponsor: Burke Medical Research Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: White Plains, New York

Conditions: Friedreich Ataxia
Interventions: Methylprednisolone; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 5 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Friedreich Ataxia
Interventions: Nomlabofusp, Placebo; Drug
Lead sponsor: Larimar Therapeutics, Inc.; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Chevy Chase, Maryland

Conditions: Friedreich Ataxia
Interventions: CTI-1601, Placebo; Biological · Other
Lead sponsor: Larimar Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Eatontown, New Jersey

Conditions: Friedreich Ataxia
Interventions: Omaveloxolone; Drug
Lead sponsor: Biogen; Industry
Eligibility: 2 Years to 15 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Friedreich Ataxia
Interventions: Natural history; Other
Lead sponsor: Monash University; Other
Eligibility: 5 Years and older
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 3
States / cities: Gainesville, Florida • Minneapolis, Minnesota • Philadelphia, Pennsylvania

Conditions: Friedreich's Ataxia
Interventions: NBIB-0000223; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 8 Years to 40 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 5
States / cities: Los Angeles, California • Gainesville, Florida • Tampa, Florida + 2 more

Conditions: Friedreich's Ataxia
Interventions: varenicline, placebo; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years to 80 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Tampa, Florida • Philadelphia, Pennsylvania

Conditions: Friedreich Ataxia
Interventions: TAK-831, TAK-831 Placebo; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 6
States / cities: Los Angeles, California • Gainesville, Florida • Tampa, Florida + 3 more

Conditions: Friedreich Ataxia
Interventions: Omaveloxolone Capsules, 2.5 mg, Omaveloxolone Capsules, 5 mg, Omaveloxolone Capsules, 10 mg, Placebo, Omaveloxolone Capsules, 20 mg, Omaveloxolone Capsules, 40 mg, Omaveloxolone Capsules, 80 mg, Omaveloxolone Capsules, 160 mg, Omaveloxolone Capsules, 300 mg, Omaveloxolone Capsules, 150 mg; Drug
Lead sponsor: Biogen; Industry
Eligibility: 16 Years to 40 Years
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 7
States / cities: Los Angeles, California • Gainesville, Florida • Tampa, Florida + 4 more

Conditions: Friedreich Ataxia
Interventions: Not listed
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 2 Years to 18 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 3
States / cities: Los Angeles, California • Gainesville, Florida • Philadelphia, Pennsylvania

Conditions: Friedreich Ataxia
Interventions: Not listed
Lead sponsor: Friedreich's Ataxia Research Alliance; Other
Eligibility: Not listed
Enrollment: 3,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2048
U.S. locations: 9
States / cities: Los Angeles, California • Denver, Colorado • Gainesville, Florida + 6 more

Conditions: Friedreich Ataxia
Interventions: Vatiquinone; Drug
Lead sponsor: PTC Therapeutics; Industry
Eligibility: Up to 6 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Iron-sulfur Cluster Deficiency, Pulmonary Hypertension, Friedreich Ataxia
Interventions: Right Heart Catheterization, Blood draw; Procedure · Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 60 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Friedreich's Ataxia
Interventions: Vatiquinone; Drug
Lead sponsor: PTC Therapeutics; Industry
Eligibility: 7 Years to 21 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 4
States / cities: Los Angeles, California • Tampa, Florida • Iowa City, Iowa + 1 more

Conditions: Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia Type 3, Spinocerebellar Ataxia Type 6, Friedreich Ataxia
Interventions: Not listed
Lead sponsor: University of Chicago; Other
Eligibility: 12 Years to 75 Years
Enrollment: 128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 5
States / cities: Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 2 more

Conditions: Friedreich Ataxia
Interventions: MIB-626; Drug
Lead sponsor: Metro International Biotech, LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Friedreich Ataxia, Cardiomyopathy, Secondary
Interventions: Low dose LX2006, Mid Dose LX2006, High Dose LX2006; Genetic
Lead sponsor: Lexeo Therapeutics; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 3
States / cities: Los Angeles, California • Tampa, Florida • Rochester, Minnesota

Conditions: Friedreich's Ataxia
Interventions: interferon γ-1b; Drug
Lead sponsor: Amgen; Industry
Eligibility: 11 Years to 27 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 4
States / cities: Los Angeles, California • Gainesville, Florida • Iowa City, Iowa + 1 more

Search by objective public record fields.

FRDA Investigator Initiated Study (IIS) With Elamipretide

GV101 for Friedreich's Ataxia (FA) Treatment

Preliminary Study of the Scale To Assess Ataxia and Neurologic Dysfunction (STAND)

A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Who Are Prescribed it by Their Own Doctors

A Study of SGT-212 Gene Therapy in Friedreich's Ataxia

Home Based Tele-exercise for People With Chronic Neurological Impairments

Methylprednisolone Treatment of Friedreich Ataxia

A Study to Assess Nomlabofusp in Adolescents and Children With Friedreich's Ataxia

A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's Ataxia

A Study to Find Out How BIIB141 (Omaveloxolone) is Processed in the Body and to Learn More About Its Safety in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old

A Natural History Study to TRACK Brain and Spinal Cord Changes in Individuals with Friedreich Ataxia (TRACK-FA)

Study of NBIB-223 Gene Therapy in Friedreich's Ataxia (FACET)

Pilot Study of Varenicline (Chantix®) in the Treatment of Friedreich's Ataxia

Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxia

A Study to Learn About the Effects and Safety of RTA 408 (Omaveloxolone) in People Aged 16 to 40 With Friedreich's Ataxia

Neurology Measures in FA Children

Friedreich Ataxia Global Clinical Consortium UNIFIED Natural History Study

A Study of Vatiquinone for the Treatment of Participants With Friedreich Ataxia

Genetic and Environmental Determinants That Control Metabolism in Pulmonary Hypertension

Long-Term Efficacy Study of Vatiquinone for the Treatment of Friedreich's Ataxia (FA)

Instrumented Data Exchange for Ataxia Study

NAD+ Precursor Supplementation in Friedreich's Ataxia

Gene Therapy for Cardiomyopathy Associated With Friedreich's Ataxia

Long-Term Safety Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia